Login / Signup

Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.

Katrine Bagge HansenMathilde SvendstrupAsger LundFilip K KnopTina VilsbøllHenrik Vestergaard
Published in: Diabetic medicine : a journal of the British Diabetic Association (2021)
We observed effects of semaglutide once weekly on HbA1c and body weight comparable with the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide.
Keyphrases
  • body weight
  • type diabetes
  • cardiovascular disease
  • primary care
  • case report
  • electronic health record
  • glycemic control
  • metabolic syndrome
  • data analysis
  • replacement therapy
  • artificial intelligence